Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of “Hold” by Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR) have been given an average recommendation of “Hold” by the ten ratings firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $24.50.

Several analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. JPMorgan Chase & Co. increased their price target on shares of Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Monday, May 11th. Zacks Research downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a report on Friday, March 27th. Finally, Barclays increased their price target on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, February 26th.

Xencor Trading Up 10.8%

NASDAQ XNCR opened at $14.01 on Thursday. The company has a fifty day simple moving average of $12.15 and a 200 day simple moving average of $12.91. The company has a market cap of $1.04 billion, a P/E ratio of -6.12 and a beta of 0.92. Xencor has a 1 year low of $6.92 and a 1 year high of $18.69.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The firm had revenue of $4.52 million for the quarter, compared to the consensus estimate of $27.86 million. Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.Xencor’s quarterly revenue was down 86.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.66) earnings per share. Equities research analysts forecast that Xencor will post -3.84 EPS for the current fiscal year.

Institutional Trading of Xencor

A number of hedge funds have recently bought and sold shares of XNCR. BVF Inc. IL boosted its holdings in Xencor by 160.3% in the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock valued at $109,217,000 after purchasing an additional 4,393,579 shares during the period. Legal & General Group Plc boosted its holdings in Xencor by 603.7% in the 3rd quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock valued at $14,932,000 after purchasing an additional 1,092,095 shares during the period. State Street Corp boosted its holdings in Xencor by 22.7% in the 4th quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after purchasing an additional 833,423 shares during the period. Jefferies Financial Group Inc. boosted its holdings in Xencor by 620.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock valued at $11,030,000 after purchasing an additional 620,440 shares during the period. Finally, RTW Investments LP boosted its holdings in Xencor by 8.9% in the 4th quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock valued at $103,763,000 after purchasing an additional 556,407 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.